...
search icon
adct-img

ADC Therapeutics SA, Common Stock

ADCT

NYQ

$3.03

-$0.23

(-7.06%)

1D
Industry: Communications Equipment Sector: Information Technology

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$364.17M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.96
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.05 L
$4.13 H
$3.03

About ADC Therapeutics SA, Common Stock

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. more

Industry: Communications EquipmentSector: Information Technology

Returns

Time FrameADCTSectorS&P500
1-Week Return-14.16%0.53%-0.63%
1-Month Return29.49%3.01%0.46%
3-Month Return71.19%13.89%6.48%
6-Month Return58.64%4.03%1.89%
1-Year Return11.4%4.41%8.94%
3-Year Return-55.31%89.56%58.67%
5-Year Return-92.48%134.69%91.64%
10-Year Return-89.78%460.71%181.75%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-33.92M209.91M69.56M69.28M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":16.16,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":33.14,"profit":true},{"date":"2024-12-31","value":33,"profit":true}]
Cost of Revenue1.97M1.39M4.58M2.53M5.95M[{"date":"2020-12-31","value":33.15,"profit":true},{"date":"2021-12-31","value":23.42,"profit":true},{"date":"2022-12-31","value":76.97,"profit":true},{"date":"2023-12-31","value":42.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(1.97M)32.52M205.33M67.03M63.33M[{"date":"2020-12-31","value":-0.96,"profit":false},{"date":"2021-12-31","value":15.84,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":32.64,"profit":true},{"date":"2024-12-31","value":30.84,"profit":true}]
Gross Margin-95.89%97.82%96.36%91.41%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":98.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.51,"profit":true},{"date":"2024-12-31","value":93.45,"profit":true}]
Operating Expenses219.26M294.24M328.96M233.01M192.27M[{"date":"2020-12-31","value":66.65,"profit":true},{"date":"2021-12-31","value":89.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.83,"profit":true},{"date":"2024-12-31","value":58.45,"profit":true}]
Operating Income(219.26M)(261.72M)(123.63M)(165.99M)(130.65M)[{"date":"2020-12-31","value":-21926300000,"profit":false},{"date":"2021-12-31","value":-26172000000,"profit":false},{"date":"2022-12-31","value":-12362700000,"profit":false},{"date":"2023-12-31","value":-16598600000,"profit":false},{"date":"2024-12-31","value":-13065400000,"profit":false}]
Total Non-Operating Income/Expense(30.79M)(8.06M)(52.51M)(69.01M)(63.42M)[{"date":"2020-12-31","value":-3079400000,"profit":false},{"date":"2021-12-31","value":-805900000,"profit":false},{"date":"2022-12-31","value":-5251100000,"profit":false},{"date":"2023-12-31","value":-6901000000,"profit":false},{"date":"2024-12-31","value":-6342100000,"profit":false}]
Pre-Tax Income(245.96M)(251.50M)(154.66M)(195.42M)(156.14M)[{"date":"2020-12-31","value":-24596300000,"profit":false},{"date":"2021-12-31","value":-25150500000,"profit":false},{"date":"2022-12-31","value":-15466100000,"profit":false},{"date":"2023-12-31","value":-19541900000,"profit":false},{"date":"2024-12-31","value":-15613600000,"profit":false}]
Income Taxes327.00K(21.48M)1.14M39.11M166.00K[{"date":"2020-12-31","value":0.84,"profit":true},{"date":"2021-12-31","value":-54.93,"profit":false},{"date":"2022-12-31","value":2.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":0.42,"profit":true}]
Income After Taxes(246.29M)(230.03M)(155.80M)(234.53M)(156.30M)[{"date":"2020-12-31","value":-24629000000,"profit":false},{"date":"2021-12-31","value":-23002600000,"profit":false},{"date":"2022-12-31","value":-15580000000,"profit":false},{"date":"2023-12-31","value":-23452500000,"profit":false},{"date":"2024-12-31","value":-15630200000,"profit":false}]
Income From Continuous Operations(246.29M)(230.03M)(155.80M)(178.51M)(157.85M)[{"date":"2020-12-31","value":-24629000000,"profit":false},{"date":"2021-12-31","value":-23002600000,"profit":false},{"date":"2022-12-31","value":-15580000000,"profit":false},{"date":"2023-12-31","value":-17850700000,"profit":false},{"date":"2024-12-31","value":-15784600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(246.29M)(230.03M)(155.80M)(240.05M)(157.85M)[{"date":"2020-12-31","value":-24629000000,"profit":false},{"date":"2021-12-31","value":-23002600000,"profit":false},{"date":"2022-12-31","value":-15580000000,"profit":false},{"date":"2023-12-31","value":-24005300000,"profit":false},{"date":"2024-12-31","value":-15784600000,"profit":false}]
EPS (Diluted)(4.16)(2.80)(2.01)(2.93)(1.65)[{"date":"2020-12-31","value":-416,"profit":false},{"date":"2021-12-31","value":-280,"profit":false},{"date":"2022-12-31","value":-201,"profit":false},{"date":"2023-12-31","value":-293,"profit":false},{"date":"2024-12-31","value":-165,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ADCT
Cash Ratio 3.37
Current Ratio 4.46
Quick Ratio 4.16

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ADCT
ROA (LTM) -27.03%
ROE (LTM) -705.53%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ADCT
Debt Ratio Lower is generally better. Negative is bad. 1.87
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.87

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ADCT
Trailing PE NM
Forward PE NM
P/S (TTM) 4.27
P/B 2.58
Price/FCF NM
EV/R 3.32
EV/Ebitda NM

FAQs

What is ADC Therapeutics SA share price today?

ADC Therapeutics SA (ADCT) share price today is $3.03

Can Indians buy ADC Therapeutics SA shares?

Yes, Indians can buy shares of ADC Therapeutics SA (ADCT) on Vested. To buy ADC Therapeutics SA from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ADCT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of ADC Therapeutics SA be purchased?

Yes, you can purchase fractional shares of ADC Therapeutics SA (ADCT) via the Vested app. You can start investing in ADC Therapeutics SA (ADCT) with a minimum investment of $1.

How to invest in ADC Therapeutics SA shares from India?

You can invest in shares of ADC Therapeutics SA (ADCT) via Vested in three simple steps:

  • Click on Sign Up or Invest in ADCT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in ADC Therapeutics SA shares
What is ADC Therapeutics SA 52-week high and low stock price?

The 52-week high price of ADC Therapeutics SA (ADCT) is $4.13. The 52-week low price of ADC Therapeutics SA (ADCT) is $1.05.

What is ADC Therapeutics SA price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of ADC Therapeutics SA (ADCT) is 2.58

What is the Market Cap of ADC Therapeutics SA?

The market capitalization of ADC Therapeutics SA (ADCT) is $364.17M

What is ADC Therapeutics SA’s stock symbol?

The stock symbol (or ticker) of ADC Therapeutics SA is ADCT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top